Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Scientific Off/HeadR&D | February 06, 2019 | February 09, 2019 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,828 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 8,323 · Balance 35,177 F4: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 16, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Row 2 · 2019-02-06 · Grant · Acquired 7,104 · Balance 42,281 F5: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 4,453 · Balance 37,828 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.75 · Expires 2029-02-06 | Direct | 67,310 |
Reported balance
After 2019-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-06 · Grant · Acquired 67,310 · Balance 67,310 F1: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,015 |
Reported balance
After 2019-02-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-06 · Grant · Acquired 14,550 · Balance 16,015 F2: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F2: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F3: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
F4: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 16, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.
F5: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 21:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-259855 · ownership.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $15.81 | $0.00 |
DisclosureSEC source: 0000950170-25-083702 · ownership.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| March 31, 2025 Filed Apr 15, 2025 21:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 757 | $9.85 | $7,455.01 |
DisclosureSEC source: 0000950170-25-054331 · ownership.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,347 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.56 to $10.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $15.06 | $0.00 |
DisclosureSEC source: 0000950170-24-066605 · ownership.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2034-05-29 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 29, 2025 and (2) the date of the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 2,117 | $14.93 | $31,614.85 |
DisclosureSEC source: 0000950170-24-064586 · ownership.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,104 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,206 | $13.07 | $15,764.71 |
DisclosureSEC source: 0000950170-24-040205 · ownership.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,221 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. F3 · balance_after: Reflects equitable adjustment of the number of shares beneficially owned by the reporting person resulting from a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2023, which is exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:35 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001209191-23-032900 · doc4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2024 and (2) the date of the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 25,972 | $1.04 | $27,018.67 |
DisclosureSEC source: 0001209191-23-031919 · doc4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,160 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 117,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031919 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,132 F1 · shares: Represents shares of common stock issuable under a performance-based restricted stock unit award dated July 22, 2021. On May 22, 2023, the performance-based vesting conditions were achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: May 22, 2023 and May 22, 2024. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 20:45 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 14,883 | $0.82 | $12,251.69 |
DisclosureSEC source: 0001209191-23-021886 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,632 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7795 to $0.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 12,314 | $2.13 | $26,200.50 |
DisclosureSEC source: 0001209191-22-045239 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,515 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.08 to $2.21, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 18, 2022 Filed Sep 6, 2022 19:25 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001209191-22-048886 · doc4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 20:36 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 4,614 | $2.17 | $10,000.38 |
DisclosureSEC source: 0001209191-22-021770 · doc4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,829 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:36 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantPerformance-based Restricted Stock Units · Derivative | 83,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021770 · doc4.xml · derivative · entry 4 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,750 Underlying: Common Stock · 83,750 shares Expires 2027-03-29 F5 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction. F5 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:36 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 335,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-22-021770 · doc4.xml · derivative · entry 3 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 Underlying: Common Stock · 335,000 shares Expires 2032-03-29 F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 20:36 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 83,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021770 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,443 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:09 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 12,156 | $3.60 | $43,781.05 |
DisclosureSEC source: 0001209191-21-050645 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,693 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 24, 2021 Filed May 25, 2021 18:54 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-21-035772 · doc4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-05-23 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| March 29, 2021 Filed Apr 2, 2021 20:35 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 305,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001209191-21-024621 · doc4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 305,000 shares Expires 2031-03-29 F1 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:34 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 756 | $22.50 | $17,009.62 |
DisclosureSEC source: 0001209191-20-045952 · doc4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,849 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.39 to $22.62, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:34 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 11,395 | $21.76 | $247,907.34 |
DisclosureSEC source: 0001209191-20-045952 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,605 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.38 to $22.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 20:12 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001209191-20-021796 · doc4.xml · derivative · entry 2 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-27 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on March 29, 2021; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2024. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 20:12 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021796 · doc4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2021; March 29, 2022; March 29, 2023; and March 29, 2024. Read SEC document |
| September 28, 2019 Filed Oct 1, 2019 22:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantPerformance-based Restricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051355 · doc4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-09-28 F1 · derivative.exercise_price: Each performance-based Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Assembly Biosciences, Inc. common stock. The shares of common stock are earned if market-based performance metrics are met (the "Milestone") on or before the third anniversary of the grant date. If the Milestone is achieved on or before the second anniversary of the grant date, then the RSUs shall become fully vested on the second anniversary of the grant date. If the Milestone is achieved after the second anniversary of the grant date and on or before the third anniversary of the grant date, then the RSUs shall become fully vested on the third anniversary of the grant date. Any RSU that has not been earned and vested as of the third anniversary of the grant will be forfeited. F1 · derivative.exercise_date: Each performance-based Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Assembly Biosciences, Inc. common stock. The shares of common stock are earned if market-based performance metrics are met (the "Milestone") on or before the third anniversary of the grant date. If the Milestone is achieved on or before the second anniversary of the grant date, then the RSUs shall become fully vested on the second anniversary of the grant date. If the Milestone is achieved after the second anniversary of the grant date and on or before the third anniversary of the grant date, then the RSUs shall become fully vested on the third anniversary of the grant date. Any RSU that has not been earned and vested as of the third anniversary of the grant will be forfeited. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 22:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001144204-19-038644 · tv527181_4.xml · derivative · entry 2 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-08-06 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over three years, assuming continuous service on each vesting date, as follows: one-third will vest on the first anniversary of the date of grant, August 6, 2020; and the remaining two-thirds will vest in 24 approximately equal monthly installments, with the options becoming fully vested on August 6, 2022. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 22:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-038644 · tv527181_4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Grant of restricted stock units. The restricted stock units vest in three approximately equal installments, assuming continuous service on each vesting date, as follows: August 6, 2020; August 6, 2021; and August 6, 2022. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 14,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004925 · form4.xml · derivative · entry 5 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,015 Underlying: Common Stock · 14,550 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 67,310 | $0.00 Strike: $68.75 | $0.00 |
DisclosureSEC source: 0001127602-19-004925 · form4.xml · derivative · entry 4 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,310 Underlying: Common Stock · 67,310 shares Expires 2029-02-06 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,453 | $68.75 | $306,143.75 |
DisclosureSEC source: 0001127602-19-004925 · form4.xml · nonDerivative · entry 3 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,828 Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 7,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004925 · form4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,281 F5 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 8,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004925 · form4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,177 F4 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 16, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 19:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,988 | $65.12 | $194,578.56 |
DisclosureSEC source: 0001127602-18-036847 · form4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,854 Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 19:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 6,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036847 · form4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on December 17, 2018. Read SEC document |
| November 10, 2018 Filed Nov 13, 2018 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032917 · form4.xml · derivative · entry 3 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,465 Underlying: Common Stock · 1,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2018 Filed Nov 13, 2018 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 664 | $71.18 | $47,263.52 |
DisclosureSEC source: 0001127602-18-032917 · form4.xml · nonDerivative · entry 2 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,707 Read SEC document |
| November 10, 2018 Filed Nov 13, 2018 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-032917 · form4.xml · nonDerivative · entry 1 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 79,710 | $65.22 Strike: $65.22 | $5,198,686.20 |
DisclosureSEC source: 0001127602-18-017110 · form4.xml · derivative · entry 1 McHutchison John G · CIK 0001738125 · Chief Scientific Off/HeadR&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,710 Underlying: Common Stock · 79,710 shares Expires 2028-05-08 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.